Oxaliplatin
Product Images NDC 47335-047

This is a description for Oxaliplatin Injection, a cytotoxic agent, for intravenous use only. Each 1 mL contains 5 mg of Oxaliplatin, with Water for Injection as inactive ingredients. It requires further dilution in 5% dextrose injection, after which it should not be frozen or exposed to light. It should be retained in the carton until time of use and stored at 20°C to 25°C (68°F to 77°F). Any unused portion should be discarded, and the diluted solution should be stored according to the package insert. Manufactured by Sun Pharmaceutical Industries Ltd, and distributed by Sun Pharmaceutical Industries, Inc. It is a single-use vial only and should not be mixed or added to sodium chloride or chloride-containing solutions.*

Oxaliplatin Injection, USP is a cytotoxic agent for intravenous use. It is packaged in a single-use vial and contains 5 mg of Oxaliplatin, USP in each mL. The inactive ingredients are water for injection. The usual dosage is further diluted in 5% dextrose injection. The medicine should not be frozen and must be protected from light. It should be stored at 20°to 25°C (68° to 77°F), and unused portions must be discarded. The drug is distributed by Sun Pharmaceutical Industries, Inc. and is manufactured by Sun Pharmaceutical Industries Ltd, under license from Sanofi-Aventis U.S. LLC, Sanofi-Aventis, and Debiopharm S.A.*

This text appears to be a medical prescription outlining dosages and timings for administering drugs to a patient. The drugs mentioned include 5-FU bolus, Leucovorin, and Oxaliplatin. Dosages are given in milligrams per square meter of the patient's body over specific time periods, and some instructions indicate multiple doses given over the course of two days. Overall, this text is likely not useful for a general audience and should be interpreted only by medical professionals.*

This is a statistical analysis of the DFS (disease-free survival) probability of two arms (FOLFOX4 and LVSFU2) in a clinical trial. The table shows the number of events (i.e., recurrence of a disease) and the hazard ratio, as well as the p-value for the stratified logrank test. The graph shows the DFS probability over time (in months) for both arms.*

This appears to be a graph showing DFS (disease-free survival) probability over time for two treatment arms in a study (FOLFOX4 and LV5FU2) for patients with Dukes C colon cancer. The hazard ratio and p-value are also provided.*

This is a chart displaying the median survival rates for different treatments. The treatments include Oxaliplatin Injection + 5-FU/LY, Oxaliplatin Injection + Irinotecan, and Irinotecan + 5-FU/LY. The chart also includes the percentage of patients surviving and a comparison between Oxaliplatin Injection + 5-FU/LV and Irinotecan + 5-FU/LV using a log-rank test. The numbers on the bottom seem to represent months.*

This is a description of a medication called Oxaliplatin Injection. It is a cytotoxic agent that contains 5mg of oxaliplatin per mL and is intended for intravenous use only. The injection must be stored at 20°C to 25°C, and caution must be taken not to freeze or expose it to light. The medication is distributed by Sun Pharmaceutical Industries, Inc. and is packaged in a single-use vial. The package insert provides information on the required dilution and storage of further diluted solutions. The medication should not be mixed or added to solutions containing sodium chloride/chloride. The usual dosage is further diluted in 5% dextrose. The manufacturing company is Sun Pharmaceutical Industries Ltd. located in India, and it is manufactured under license from Sanofi-Aventis U.S. LLC, Sanofi-Aventis, and Debiopharm S.A. There is also an expiration date provided.*

Oxaliplatin Injection is a sterile, preservative-free cytotoxic agent used for intravenous use only in single-use vials. Each mL contains USP 5 mg oxaliplatin and water for injection. The medication must be further diluted in 5% dextrose injection, USP, but cannot be frozen or exposed to light. The medication should be kept in the carton until use and stored at 20°C to 25°C. Any unused portions must be discarded. The package insert should be consulted for dilution and storage information. The medication is distributed by Sun Pharmaceutical Industries, Inc. in Cranbury, NJ, and manufactured by Sun Pharmaceutical Industries Ltd. in Gujarat, India, under license from Sanofi-Aventis U.S. LLC, Sanofi-Aventis, and Debiopharm S.A.*